DexCom, Inc. (NASDAQ:DXCM) Stock Has Average Target Price of $92.43

Shares of DexCom, Inc. (NASDAQ:DXCM) have received a consensus recommendation of “Buy” from the twenty-four analysts that are presently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and three have given a strong buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $92.43.

A number of research firms recently commented on DXCM. Benchmark lifted their target price on shares of DexCom from $77.00 to $82.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Robert W. Baird set a $105.00 target price on shares of DexCom in a report on Friday, July 31st. TD Cowen reiterated a “buy” rating and set a $95.00 price target on shares of DexCom in a research report on Friday, September 18th. Weiss Ratings raised shares of DexCom from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, October 6th. Finally, UBS Group set a $96.00 price objective on DexCom and gave the stock a “buy” rating in a research report on Tuesday, July 28th.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 2,565 shares of DexCom stock in a transaction that occurred on Monday, September 28th. The shares were sold at an average price of $86.15, for a total value of $220,974.75. Following the completion of the transaction, the executive vice president owned 123,478 shares in the company, valued at $10,637,629.70. The trade was a 2.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark Foletta sold 2,000 shares of the stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $85.32, for a total value of $170,640.00. Following the completion of the transaction, the director owned 48,852 shares in the company, valued at approximately $4,168,052.64. The trade was a 3.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 24,257 shares of company stock worth $2,049,173 over the last ninety days. Company insiders own 0.28% of the company’s stock.

Hedge Funds Weigh In On DexCom

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Plato Investment Management Ltd acquired a new position in shares of DexCom during the 2nd quarter worth $782,000. Aurora Investment Counsel purchased a new position in shares of DexCom during the 2nd quarter worth $2,340,000. E Fund Management Co. Ltd. purchased a new stake in DexCom in the 2nd quarter valued at about $1,273,000. Silvant Capital Management LLC acquired a new position in DexCom during the second quarter worth approximately $5,359,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of DexCom during the 2nd quarter worth $89,940,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Price Performance

DXCM opened at $77.94 on Tuesday. The business has a fifty day moving average of $86.79 and a 200 day moving average of $76.54. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. The stock has a market cap of $29.41 billion, a P/E ratio of 30.81, a PEG ratio of 1.31 and a beta of 1.48. DexCom has a 52-week low of $54.11 and a 52-week high of $92.59.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The company had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. During the same period in the prior year, the business earned $0.48 EPS. The firm’s quarterly revenue was up 13.1% on a year-over-year basis. As a group, sell-side analysts anticipate that DexCom will post 2.64 EPS for the current year.

DexCom Company Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.